AGRX - Why Agile Therapeutics Stock Is Getting Crushed Today
Shares of the early commercial stage biotech Agile Therapeutics (NASDAQ: AGRX) are in a tailspin Thursday morning. The drugmaker's stock is down by 20.5% as of 10:12 a.m. EST today.
Following this latest downward move, Agile's stock has now lost over a third of its value since the start of February. That's not exactly the outcome shareholders were hoping for after the company got the green light from the Food and Drug Administration (FDA) for its weekly contraceptive patch Twirla roughly two weeks ago on Feb. 14.
Image source: Getty Images.